Real-World COPD Management Over 3 Years at the Community Health Service Center of Shanghai During the COVID-19 Pandemic in China

Ting-Ting Wu,Yi Qun Jiang,Bang-Feng Zhao,Feng-Li Si,Peng Wu,Huan-Ying Wang,Chun-Feng Sheng,Xun Xu,Fan Li,Jing Zhang

DOI: https://doi.org/10.2147/COPD.S391908

2023-03-18

International Journal of COPD

Abstract:Ting-Ting Wu, 1, &ast Yi Qun Jiang, 2, &ast Bang-Feng Zhao, 1, &ast Feng-Li Si, 1 Peng Wu, 1 Huan-Ying Wang, 1 Chun-Feng Sheng, 1 Xun Xu, 1 Fan Li, 1 Jing Zhang 3 1 Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Preparatory Stage), Shanghai, People's Republic of China; 2 General Practice/International Medical Care Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 3 Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fan Li; Jing Zhang, Email ; Objective: To evaluate the real-world situation for the management of chronic obstructive pulmonary disease (COPD) and poorly controlled disease risk factors in the Chinese community. Methods: This retrospective multicentre study analysed data from COPDMICand MICHC in Shanghai Songjiang District, Shanghai, China. The differences in COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) dyspnea scale, and the number of emergency cases, emergency visits, inpatient cases, and hospitalisations from January 2018 to December 2020 were analysed. The impact of coronavirus disease 2019 (COVID-19) on COPD management was also assessed. Results: For 2020 versus 2018, analysis of 468 COPD cases from COPDMIC matched with MICHC data showed significantly more patients with improved mMRC grades, significantly fewer emergency cases and emergency visits, and significantly fewer hospitalisation cases and hospitalisations. Differences in the number of emergency visits and hospitalisations per capita were statistically significant. Compared to GOLD 3– 4, GOLD 1– 2 patients showed significant improvements in CAT score, mMRC grade, the number of emergency visits and hospitalisations per capita. Treatment adherence from 2018 to 2020 was 25%, 29.1%, and 6.8%, and the proportion of medication regimens consistent with guidelines was 43.44%, 50.98%, and 71.87%, respectively. Higher treatment adherence resulted in significantly improved CAT scores and mMRC grades and fewer emergency department visits and hospitalisations per capita. Conclusion: Combined with remote management tools, patients with COPD achieved continuous improvement in symptoms and exacerbations over 3 years. In the context of COVID-19 prevention/control measures, improvements were significant for patients with GOLD 1– 2 COPD but limited with GOLD 3– 4. Pharmacologic treatment significantly improved clinical symptoms and reduced emergency visits and hospitalisations. Severe airflow limitation and poor adherence to pharmacologic treatment were important risk factors for lack of disease remission. Keywords: chronic obstructive, lung disease, COVID-19, family physician, management information center Chronic obstructive pulmonary disease (COPD) is a common respiratory disease globally. In China, the prevalence of COPD for individuals older than 40 years has increased in less than a decade, from 8.6% in 2007 to 13.7% in 2018, 1,2 resulting in COPD becoming the third leading cause of disability and the fourth leading cause of mortality in China. 3 Despite this high prevalence and poor outcomes, however, numerous studies have shown that the rate of early diagnosis, standardisation of initial treatment regimens (ie consistency of drug regimens with guidelines), and adherence to drug therapy are generally low in patients with COPD in China. For example, Wang Chen et al reported 2 that only 9.7% of patients with COPD in China were diagnosed based on pulmonary function, and only 3.2% of patients with COPD had a medication regimen consistent with guidelines. A national cross-sectional survey of individuals aged 40 years and older showed a diagnosis rate of 5.9% and a treatment rate of 11.7% among those with COPD. 4 In terms of treatment adherence over 1 year among patients with stable COPD in two studies, 30% were adherent for more than 50% of the year, whereas 10% were adherent for more than 80% of the year. 5,6 Therefore, improving the rate of early diagnosis, treatment standardisation, and treatment adherence of patients with COPD in China is an important issue to improve the treatment outcomes in this population. Figure 1 Flow chart of COPDMIC operations. To address this issue, we developed COPD Management Information Center (COPDMIC), which went online in 2017 (Figure 1). 7 The COPDMIC is a regional COPD -Abstract Truncated-